SAN DIEGO -- The risk of progression from smoldering multiple myeloma to symptomatic disease decreased by 50% in patients treated with the anti-CD38 monoclonal antibody daratumumab (Darzalex), ...

The U.S. Food and Drug Administration (FDA) has accepted a new drug application for iberdomide combined with Darzalex ...

Data show that patients’ multiple myeloma still fails to progress if patients receive less-frequent Tecvayli. A reduced dosing schedule of Tecvayli (teclistamab) continued to slow the progression of ...

Patients treated with ciltacabtagene autoleucel (cilta-cel; Carvykti) in the phase 3 CARTITUDE-4 trial (NCT04181827) achieved high rates of progression-free survival (PFS) at near ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

MajesTEC-9 is the second positive Phase 3 study to support TECVAYLI ® regimens as a potential new standard of care as early as first relapse RARITAN, N.J., Jan. 14, 2026 /PRNewswire/ -- Johnson & ...

A new risk assessment score developed by researchers at Dana-Farber Cancer Institute, the Broad Institute of MIT and Harvard, and Massachusetts General Hospital reveals how multiple myeloma, a form of ...

Carfilzomib prevented BCMA degradation, increased target density, and improved CAR T susceptibility by ~26%–28% in vitro, while enhancing xenograft antitumor activity without worsening T-cell ...

CAR-T treatment landscape in multiple myeloma basically has changed dramatically over the past few years.

Multiple myeloma is a relatively uncommon cancer of plasma cells, where excessive proliferation of these malignant cells within the bone marrow leads to abnormal antibody production. The disease ...

Afterward, all received lenalidomide as "maintenance" therapy to keep myeloma from coming back until progression. Half were randomly assigned to undergo an autologous stem cell transplant (which uses ...